Long Focus Capital Management LLC buys 260,594 shares of Sight Sciences, Inc. (NASDAQ:SGHT)

Long Focus Capital Management LLC lifted its position in shares of Sight Sciences, Inc. (NASDAQ:SGHT – Free Report) by 86.9% during the second quarter, HoldingsChannel reports. The fund owned 560,594 shares of the company’s stock after purchasing an additional 260,594 shares during the period. Long Focus Capital Management LLC’s holdings in Sight Sciences were worth $3,739,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in SGHT. UBS Group AG raised its stake in shares of Sight Sciences by 20,282.6% in the fourth quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock valued at $14,943,000 after purchasing an additional 2,881,750 shares during the last quarter. Vanguard Group Inc. raised its holdings in Sight Sciences by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after acquiring an additional 81,768 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in Sight Sciences by 25.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock worth $1,991,000 after acquiring an additional 76,549 shares during the period. RTW Investments LP bought a new stake in shares of Sight Sciences in the 4th quarter valued at $850,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Sight Sciences by 70.5% in the second quarter. Bank of New York Mellon Corp now owns 102,461 shares of the company’s stock worth $683,000 after purchasing an additional 42,383 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s shares.

Insider activity at Sight Sciences

In other Sight Sciences news, CFO Alison Bauerlein sold 10,497 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $6.21, for a total transaction of $65,186.37. Following the transaction, the chief financial officer now owns 402,685 shares of the company’s stock, valued at approximately $2,500,673.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Sight Sciences news, CEO Paul Badawi sold 12,569 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $6.42, for a total value of $80,692.98. Following the transaction, the chief executive officer now directly owns 5,738,160 shares in the company, valued at $36,838,987.20. The transaction was disclosed in a filing with the SEC, which is available on the SEC’s website. Also, CFO Alison Bauerlein sold 10,497 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $6.21, for a total transaction of $65,186.37. Following the completion of the transaction, the chief financial officer now owns 402,685 shares in the company, valued at approximately $2,500,673.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,774 shares of company stock worth $219,243. 28.90% of shares are owned by insiders.

Analyst upgrades and downgrades

A number of equities research analysts recently commented on SGHT shares. Lake Street Capital started coverage on Sight Sciences in a report on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a report on Monday, July 15th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Friday, August 2nd. Finally, Citigroup lifted their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a report on Wednesday, July 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Sight Sciences has a consensus rating of “Hold” and an average price target of $7.25, based on data from MarketBeat.

Get the latest stock analysis on SGHT

Sight Sciences Stocks up 2.2%

NASDAQ:SGHT opened at $6.57 on Friday. Sight Sciences, Inc. it has a 52-week low of $1.04 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50, and a current ratio of 11.01. The stock has a 50-day simple moving average of $6.67 and a 200-day simple moving average of $6.17. The company has a market cap of $326.90 million, a PE ratio of -5.87 and a beta of 2.72.

Sight Sciences (NASDAQ:SGHT – Get Free Report ) last announced its earnings results on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The business had revenue of $21.37 million during the quarter, compared to analysts’ expectations of $21.32 million. In the same quarter last year, the company posted ($0.30) earnings per share. On average, sell-side analysts expect that Sight Sciences, Inc. to record -1 EPS for the current fiscal year.

Sight Sciences Company Profile

(Free Report)

Sight Sciences, Inc, an ophthalmic medical device company, is engaged in the development and commercialization of surgical and non-surgical technologies for the treatment of eye diseases. It operates through two segments, surgical glaucoma and dry eye. The company’s products include the OMNI Surgical System, an implant-free glaucoma surgical technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and the SION Surgical Instrument, a hand-operated device used in ophthalmic surgical procedures for excision of the trabecular meshwork.

See Also

Want to see what other hedge funds own SGHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Sight Sciences, Inc. (NASDAQ:SGHT – Free Report).

Get news and reviews for Sight Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sight Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.